Literature DB >> 12121962

Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.

G Delmas1, S Park, Z W Chen, F Tan, R Kashiwazaki, L Zarif, D S Perlin.   

Abstract

Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a murine model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of more than 2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12121962      PMCID： PMC127382          DOI： 10.1128/AAC.46.8.2704-2707.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

Review 3.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

Authors:  D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.

Authors:  R Santangelo; P Paderu; G Delmas; Z W Chen; R Mannino; L Zarif; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model.

Authors:  L Zarif; J R Graybill; D Perlin; L Najvar; R Bocanegra; R J Mannino
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 8.  A comparative review of conventional and lipid formulations of amphotericin B.

Authors:  R F Robinson; M C Nahata
Journal:  J Clin Pharm Ther       Date:  1999-08       Impact factor: 2.512

Review 9.  Lipid formulations of amphotericin B: clinical efficacy and toxicities.

Authors:  A Wong-Beringer; R A Jacobs; B J Guglielmo
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

Review 10.  Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.

Authors:  B P Sawaya; J P Briggs; J Schnermann
Journal:  J Am Soc Nephrol       Date:  1995-08       Impact factor: 10.121
View more
  22 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 2.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

3.  Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.

Authors:  Pramod K Gupta; Anil K Jaiswal; Shalini Asthana; Venkatesh Teja B; Prashant Shukla; Minakshi Shukla; Neeti Sagar; Anuradha Dube; Srikanta K Rath; Prabhat R Mishra
Journal:  Br J Pharmacol       Date:  2015-05-19       Impact factor: 8.739

Review 4.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 5.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

6.  An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.

Authors:  Vijay Kumar Prajapati; Kalpna Awasthi; Thakur Prasad Yadav; Madhukar Rai; Onkar Nath Srivastava; Shyam Sundar
Journal:  J Infect Dis       Date:  2011-12-12       Impact factor: 5.226

7.  Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data.

Authors:  Leonid Kagan; Pavel Gershkovich; Kishor M Wasan; Donald E Mager
Journal:  AAPS J       Date:  2011-03-23       Impact factor: 4.009

8.  Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration.

Authors:  Peter Hnik; Ellen K Wasan; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.

Authors:  Kishor M Wasan; Ellen K Wasan; Peter Hnik
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 10.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.